A Study on Adverse Events Following Immunization Related to Covishield Vaccine Within 28 Days Among G

Abstract

Background: The declaration of COVID-19 as a pandemic was followed by a race for development of a vaccine against it. Covishield was one of the vaccines approved and successfully rolled out in many countries, including India, even before its phase III clinical trials were over. This study was done to determine the pattern of AEFI of Covishield vaccine. ACross-sectiona Methods: l study was conducted at a designated government vaccination site in Kannur District. 100 individuals above 18 years of age who had received both doses of vaccine were selected using simple random sampling. Data collected using a semi-structured questionnaire through phone interviews of the participants was analyzed using descriptive statistical analysis. The mean age of the study population w Results: as 47.37±11.9 years. 79% and 26% of individuals had experienced some form of AEFI after the 1st and 2nddose of vaccine respectively. The common AEFI reported include fever, local tenderness, malaise and headache.More number of younger participants(<45 yrs) reported AEFI after rst dose, with a signicant association between AEFI after 1st dose and age. Only minor AEFI were reported after each dose, with AEFI reported more Conclusion: commonly after the rst dose than the second dose.There was a statistically signicant association between the age of the participants and AEFI after 1st dose, with more AEFI being reported by individuals who were <45 years old. No such association was found between age and AEFI after the 2nddose of vaccine. Gender and comorbidity were not found to have any association with the reporting of AEFI.